ISB News

2017 Consilience Event

ISB hosts its annual Consilience event on May 19 at 1pm. The theme is “Integrating Diverse Approaches to Communicating the Complexities of Science.” This year’s speakers include Dan Goods and David Delgado from NASA’s Jet Propulsion Laboratory, and Afroditi Psarra from University of Washington. ISB co-founder Dr. Lee Hood will give opening remarks. Featured artist Ginny Ruffner will present her interactive augmented reality installation “Poetic Hybrids.” The goal of the Consilience program is to enrich the culture of ISB, and its affiliated networks, by featuring professionals who break barriers and work at the intersections of the humanities and sciences. The event is free and open to the public. Register and learn more at the link below.

Learn more

Recent Articles

  • Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

    For Cancer Cells, There Is More Than One Path to Drug Resistance

    In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.

  • ISB researchers

    Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis

    ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.

  • Merck and ISB Collaborate to Understand and Treat SARS-CoV-2 Infection

    Merck is collaborating with ISB and its partners to analyze blood samples and nasal swabs from Swedish Medical Center patients with SARS-CoV-2. Blood samples will be examined using proteomic, metabolomic, transcriptomics and genetic techniques to evaluate the impact of infection on different organs, and to identify potential biomarkers to predict the risk of severe disease.